An Integrative Intervention Based on Physical Activity, Nutrition and Supportive Care (the ADA Program) to Improve the Quality of Life of Breast Cancer Survivors

Sponsor
Siel Bleu (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05658341
Collaborator
Institut National de la Santé Et de la Recherche Médicale, France (Other)
160
10
2
35
16
0.5

Study Details

Study Description

Brief Summary

Despite it being one of the leading causes of cancer death among women, survival following a breast cancer diagnosis has greatly increased in high-income countries. However; this gave rise to a growing population of women living long after breast cancer with a diminished quality of life (QoL) due to the long-term effects of cancer and cancer treatment.

Exercise can improve QoL, fatigue, and other mental and physical health outcomes in this population, and is strongly recommended among breast cancer survivors, much like a healthy diet. However adherence in real-life to these recommendations is seldom satisfactory. Also, evidence regarding the effect and cost-effectiveness of concurrent healthy lifestyle behaviors compared to exercise alone is limited. Hence the need to develop pragmatic (evaluating the effectiveness of interventions in real-life conditions) theoretical-based customized interventions, which aim to improve uptake and instill long-term adherence of health lifestyle among breast cancer survivors.

ADA (Activité physique adaptée Doublée d'un Accompagnement spécifique post-cancer) is an integrative intervention based on physical activity, nutrition and supportive care. The interventions aims to improve breast cancer survivors' physical and mental health and instill long-term healthy behaviors.

Our study will be a pragmatic two-arm (ADA intervention versus control/usual care) cluster randomized controlled trial which examines the effectiveness of the ADA intervention program.

The primary endpoint will be health-related quality of life, as measured at 12-month after the start of the trial.

Several secondary outcomes will also be assessed; which include Physical activity level, relationship to food and self-efficacy.

The study aims to recruit 160 participants in total, divided into 20 activity groups (clusters) of 8 participants.

Primary analyses will be carried out on an intention to treat (ITT) basis, at both cluster and participant level. All statistical analysis will adjust for the clustering of patients within centers as a random effect.

The aim of this trial is to provide scientific evidence on the 'real-world' effectiveness of an easily generalizable trial, with clinically-significant outcomes, touching a growing number of cancer survivors.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: ADA
  • Behavioral: Usual Care
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
160 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
This will be a pragmatic two-arm (ADA intervention versus control/usual care) cluster randomized controlled trial.This will be a pragmatic two-arm (ADA intervention versus control/usual care) cluster randomized controlled trial.
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Supportive Care
Official Title:
Evaluating the Effectiveness of an Integrative Intervention Based on Physical Activity, Nutrition and Supportive Care (the ADA Program) to Improve the Quality of Life of Breast Cancer Survivors: Protocol for a Pragmatic Cluster Randomized Trial and Embedded Qualitative Study
Anticipated Study Start Date :
Dec 1, 2022
Anticipated Primary Completion Date :
Nov 1, 2024
Anticipated Study Completion Date :
Nov 1, 2025

Arms and Interventions

Arm Intervention/Treatment
Experimental: ADA intervention

The ADA intervention arm

Behavioral: ADA
The 12-weeks program will include one-hour in adapted physical activity (APA), and a discussion on relaxation techniques and the undertaking of deep breathing exercises (making them APA+ sessions). A series of "minute for nutrition" short information sheets will be distributed at the end of each session. Two workshops on "living better after breast cancer" will also be offered: one on general mobility and the other on daily nutrition. Moreover, women will be asked to set personal challenges as a method of motivational reinforcement, and will also be called for motivational check-ins at least 3 times. Follow-up calls will allow for further individualization, motivation, and the reception of participants' concerns or remarks. Further, participants in the intervention group will have access to a dedicated internet space containing several documents and videos on topics of concern to patients during the post-treatment phase.

Active Comparator: Usual Care

The usual care arm

Behavioral: Usual Care
Participants in the control group will be offered weekly APA sessions for 12 weeks, these sessions are based on current practices within the Siel Bleu organization. Sessions' content is adapted to people who have been treated for (all types) cancer and are based on current recommendations. These sessions are commonly organized by Siel Bleu in hospitals, community groups or local committees of the national league against cancer organization.

Outcome Measures

Primary Outcome Measures

  1. Health-related quality of life [12 months after the beginning of the intervention]

    The primary endpoint will be the health-related quality of life, as measured by the FACIT-F global score.. This score is based on the 27-items Functional Assessment of Cancer Therapy-General (FACT-G) scale ,and the 13-items fatigue subscale included in the FACIT-F. Higher score indicate better Quality of life.

Secondary Outcome Measures

  1. Participants' physical, social, emotional, and functional well-being [At 3 months, 6 months, and 12 months after the beginning of the intervention]

    measured separately by the Fact-F's four different subscales. Higher score indicate better Quality of life.

  2. Physical activity level [At 3 months, 6 months, and 12 months after the beginning of the intervention]

    Measured with the short version of the International Physical Activity Questionnaire (IPAQ).A higher IPAQ score indicates a better physical activity level..

  3. Motivation for physical activity Questionnaire-2 (BREQ-2) scale [At 3 months, 6 months, and 12 months after the beginning of the intervention]

    assessed with the Behavioral Regulation in Exercise Questionnaire-2 (BREQ-2). A higher BREQ-2 score indicates a better exercise motivation.

  4. Sedentary behavior (sitting time) [At 3 months, 6 months, and 12 months after the beginning of the intervention]

    measured with a questionnaire adapted from the Recent Physical Activity Questionnaire (RPAQ) A higher RPAQ score indicates a lower sedentary behavior level.

  5. Relationship to food [At 3 months, 6 months, and 12 months after the beginning of the intervention]

    Measured using a scale adapted from the Positive Eating Scale. A Higher score indicates a positive relationship with eating.

  6. Self-efficacy [At 3 months, 6 months, and 12 months after the beginning of the intervention]

    people's beliefs about their ability to produce designated levels of performance that influence events that affect their lives, assessed by an ad-hoc scale

  7. Health-related quality of life [3 months, and 6 months after the beginning of the intervention]

    measured by the FACIT-F global score. This score is based on the 27-items Functional Assessment of Cancer Therapy-General (FACT-G) scale ,and the 13-items fatigue subscale included in the FACIT-F. Higher score indicate better Quality of life.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 70 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • adult women who are between 18 and 70 years of age

  • had a diagnosis of localized breast cancer of any type, and who have completed their treatment (surgery, chemotherapy, radiotherapy) within the last 15 months, or still undergoing hormone therapy or nearing the end of their Herceptin treatment.

  • French-speaking

  • covered by the French Social Security system or benefiting from a similar health insurance system

Exclusion Criteria:
  • A cancer diagnosis other than breast cancer, or a relapse/metastasis of breast cancer, or generalized cancer,

  • A medical contraindication to exercise (a medical certificate of absence of contraindication to the practice of physical activity will be required, as for all physical activity in community settings).

  • Significant visual or auditory problems or behavioral problems that make it difficult to participate in group physical activity sessions.

  • a plan of moving away from the study site.

  • participating in another clinical trial

  • already enrolled in an adapted exercise workshop (outside of the ADA study)

  • Male sex

Contacts and Locations

Locations

Site City State Country Postal Code
1 Marseille Marseille Bouches DU RHON France 13
2 La Rochelle La Rochelle Charentes-maritimes France 17
3 Dijon Dijon Cote D'or France 21
4 Brest Brest Finistere France 29
5 Laval Laval Mayenne France 53
6 Lille Lille Nord France 59
7 Creil Creil Oise France 60
8 Lyon Lyon Rhone France 69
9 La Roche sur Yon La Roche-sur-Yon Vendée France 85
10 Sens Sens Yonne France 89

Sponsors and Collaborators

  • Siel Bleu
  • Institut National de la Santé Et de la Recherche Médicale, France

Investigators

  • Principal Investigator: Gwenn Menvielle, PhD, Institut National de la Santé Et de la Recherche Médicale, France
  • Principal Investigator: Patricia Dargent, PhD, Institut National de la Santé Et de la Recherche Médicale, France
  • Study Chair: Fabienne El Khoury, PhD, Institut National de la Santé Et de la Recherche Médicale, France

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Siel Bleu
ClinicalTrials.gov Identifier:
NCT05658341
Other Study ID Numbers:
  • ADA
First Posted:
Dec 20, 2022
Last Update Posted:
Dec 20, 2022
Last Verified:
Dec 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Siel Bleu
Additional relevant MeSH terms:

Study Results

No Results Posted as of Dec 20, 2022